Clinical Trial Update: A Study of rhBMP-2/CPM in Closed Fractures of the Humerus [Phase 2]

View source ↗

Summary

Wyeth/Pfizer completed a Phase 2 study evaluating rhBMP-2/CPM for closed fractures of the humerus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Humerus Fracture

Drugs mentioned

• rhBMP-2/CPM (recombinant human bone morphogenetic protein-2 with calcium phosphate matrix)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Fractures | Phase 2 | Status: COMPLETED